Lifecare ASA, together with its subsidiaries, operates as a medical sensor company that develops technology for sensing and monitoring of various body analytes in Norway and United Kingdom. The company develops Sencell, a 3D printed nano-sensor for monitoring glucose levels in patients with diabetes and for veterinary applications; as well as medical devices that remove subdermal implants. Lifecare ASA was founded in 2006 and is headquartered in Bergen, Norway.…
LIFE: Lifecare ASA Q3 2026 results
Lifecare (OSL: LIFE) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 22 employees.
The shares were at 0.3445 NOK on 20 November 2026, down 92.8% over 52 weeks. Its 52-week range is 0.2700 NOK to 5.860 NOK: the price is 94.1% below the high and 27.6% above the low.
Its market capitalisation is 148.26M NOK.
Lifecare reports return on equity of 438.8% and revenue down 21.8% year over year.
It holds more cash than debt, a net cash position of 21.54M NOK. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 0.3500 NOK is 1.6% above the current price.